InnerMost PBC: Company Profile

Background

Overview

InnerMost PBC is a New York City-based public benefit corporation dedicated to advancing psychedelic-assisted therapy. Established in February 2023, the organization integrates accessible care, practitioner training, FDA-authorized clinical trials, and community building under one roof. Its mission is to redefine mental healthcare by providing evidence-based psychedelic therapies and fostering a supportive community for clinicians and patients alike.

Mission and Vision

InnerMost PBC aims to eliminate socioeconomic barriers to accessing psychedelic therapies, ensuring that these innovative treatments are available to all individuals seeking mental health support. The organization envisions a future where psychedelic-assisted therapy is a mainstream, effective, and accessible option for mental health treatment.

Primary Area of Focus

The organization focuses on integrating psychotherapy with psychedelic substances such as ketamine and Spravato, offering both individual and group therapy sessions. Additionally, InnerMost PBC serves as an FDA-authorized clinical trial site, contributing to the advancement of psychedelic research. The center also provides comprehensive training programs for therapists, including practicum training, mentorship, and clinical supervision.

Industry Significance

As a public benefit corporation, InnerMost PBC plays a pivotal role in advancing the field of psychedelic-assisted therapy. By combining clinical services, research, and education, the organization contributes to the global understanding and acceptance of psychedelic therapies as legitimate and effective mental health treatments.

Key Strategic Focus

Core Objectives

Accessible Care: Provide affordable and effective psychedelic-assisted therapy to individuals seeking mental health support.

Therapist Training: Develop and implement comprehensive training programs for therapists specializing in psychedelic-assisted therapy.

Clinical Research: Conduct and participate in FDA-authorized clinical trials to advance the scientific understanding of psychedelic therapies.

Community Building: Foster a supportive community among clinicians and patients to share knowledge, experiences, and resources.

Specific Areas of Specialization

InnerMost PBC specializes in integrating psychedelic substances with psychotherapy, focusing on treatments such as ketamine and Spravato. The organization also emphasizes the importance of trauma-informed care and evidence-based practices in its therapeutic approaches.

Key Technologies Utilized

While specific technologies are not detailed in the available sources, InnerMost PBC likely employs advanced therapeutic techniques, data analytics for research purposes, and digital platforms for training and community engagement.

Primary Markets or Conditions Targeted

The organization primarily targets individuals seeking alternative mental health treatments, particularly those with conditions such as depression, anxiety, PTSD, and other mood disorders. By offering psychedelic-assisted therapy, InnerMost PBC aims to provide effective solutions for individuals who have not found success with traditional treatments.

Financials and Funding

Funding History

As a public benefit corporation, InnerMost PBC's funding details are not publicly disclosed. The organization is committed to transparency and may provide financial information upon request.

Total Funds Raised

Specific figures regarding total funds raised are not available in the provided sources.

Notable Investors

Information about individual investors or funding sources is not publicly disclosed.

Intended Utilization of Capital

While specific details are not provided, it is reasonable to infer that capital is utilized to support the organization's clinical services, research initiatives, therapist training programs, and community-building efforts.

Pipeline Development

Key Pipeline Candidates

InnerMost PBC is involved in FDA-authorized clinical trials, including ongoing MDMA research. The organization is also exploring future integrative mental health modalities, indicating a commitment to expanding its therapeutic offerings.

Stages of Clinical Trials or Product Development

The organization serves as a clinical trial site, participating in various stages of research, including ongoing MDMA studies. Specific details about other pipeline candidates or stages are not provided in the available sources.

Target Conditions

The clinical trials and treatments focus on mental health conditions such as depression, anxiety, PTSD, and other mood disorders.

Relevant Timelines for Anticipated Milestones

Specific timelines for clinical trial milestones or product development are not detailed in the available sources.

Technological Platform and Innovation

Proprietary Technologies

While specific proprietary technologies are not detailed, InnerMost PBC likely utilizes advanced therapeutic techniques and data analytics platforms to enhance treatment efficacy and research outcomes.

Significant Scientific Methods

The organization employs evidence-based practices, trauma-informed care, and psychedelic-assisted therapy methodologies. These approaches are grounded in scientific research and aim to provide effective mental health treatments.

AI-Driven Capabilities

There is no specific information available regarding the use of AI-driven capabilities within InnerMost PBC's operations.

Leadership Team

Key Executive Profiles

Dr. Casey Paleos, MD: Chief Medical Officer & Co-Founder. Dr. Paleos is a board-certified psychiatrist and researcher with over 15 years of experience in psychedelic-assisted therapy. He has served as a principal investigator for MAPS MDMA therapy for PTSD studies and has been involved in various psychedelic research initiatives.

Daniel Tisman, LCSW: Lead Clinical Faculty & Associate Clinical Director. Mr. Tisman provides leadership in clinical training and supervision, ensuring the integration of best practices in psychedelic-assisted therapy.

Amanda Vogel, PMHNP-BC: Clinical Nurse Manager. Ms. Vogel oversees clinical operations, ensuring the delivery of high-quality care to patients.

William Berk, MD: Physician. Dr. Berk contributes to the clinical team, providing medical oversight and expertise in psychedelic-assisted treatments.

Miles Bukiet, LMSW: Director of Clinical Culture. Mr. Bukiet fosters a supportive and effective clinical environment, promoting the organization's values and mission.

Alex Belser, PhD: Therapist. Dr. Belser provides therapeutic services, integrating psychedelic-assisted methods into patient care.

Jacob Perlson, MD: Physician. Dr. Perlson offers medical expertise, contributing to the clinical team's comprehensive care approach.

Liana Eisler: Study Coordinator. Ms. Eisler manages research studies, ensuring compliance and effective data collection.

Leadership Changes

There is no publicly available information regarding recent significant changes or appointments within InnerMost PBC's leadership team.

Competitive Landscape

Market Insights and Dynamics

The field of psychedelic-assisted therapy is emerging, with increasing interest in alternative mental health treatments. Organizations like InnerMost PBC are at the forefront, contributing to the development and acceptance of these therapies.

Competitor Analysis

Specific competitors are not detailed in the available sources. However, other organizations involved in psychedelic research and therapy may include MAPS (Multidisciplinary Association for Psychedelic Studies) and various academic institutions conducting related studies.

Strategic Collaborations and Partnerships

InnerMost PBC collaborates with various organizations and experts in the field to advance research and training in psychedelic-assisted therapy. For example, the organization hosts events and workshops in collaboration with the Psychedelic Assembly, fostering community engagement and knowledge sharing.

Operational Insights

InnerMost PBC differentiates itself through its comprehensive approach, combining clinical services, research, training, and community building. This holistic model positions the organization as a leader in the field of psychedelic-assisted therapy.

Strategic Opportunities and Future Directions

The organization is well-positioned to expand its clinical services, enhance research initiatives, and broaden its training programs. By continuing to build a supportive community and advancing scientific understanding, InnerMost PBC can further establish itself as a key player in the mental health sector.